RPRX — what changed in the latest 10-Q
A section-by-section comparison of RPRX's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-05 vs the prior 10-Q · 2026-05-06
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +78 | −52 | ~49 | 72 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Controls & procedures | Text added/removed | 0 | 0 | ~1 | 2 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Risk factors | Some risk factors updated | 0 | 0 | ~5 | 234 |
| Other information | Text added/removed | +1 | −2 | ~1 | 1 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-05
For the Three Months Ended June 30,For the Six Months Ended June 30,
Other royalty income and revenues primarily includes income from financial royalty assets that have been fully amortized, on which we may continue to collect royalties beyond the estimated duration, and income from synthetic royalties and milestones arising out of R&D funding agreements.
We enter into R&D funding agreements with counterparties to acquire royalties or milestones on product candidates. R&D funding expense consists of development-stage funding costs recognized under these agreements, which may be made upfront, as milestones upon achievement of certain predefined criter…
For the Three Months Ended June 30,ChangeFor the Six Months Ended June 30,Change
Income from financial royalty assets by top products is as follows, in order of contribution to income for the first six months of 2026 (in thousands):
Text removed vs the prior filing · source: 10-Q · 2026-05-06
Other royalty income and revenues primarily includes income from financial royalty assets that have been fully amortized and income from synthetic royalties and milestones arising out of R&D funding arrangements. Occasionally, a royalty asset may be amortized on an accelerated basis due to collectab…
R&D funding expense consists of certain development-stage funding payments that we have made to counterparties to acquire royalties or milestones on product candidates. The payments can be made on an upfront basis, upon pre-approval milestones or over time as the related product candidates undergo c…
Provision for changes in expected cash flows from financial royalty assets(197,485)(127,140)(70,345)55.3
Provision for credit losses on unfunded commitments(3,700)— (3,700)n/a
Income from financial royalty assets by top products is as follows, in order of contribution to income for the first quarter of 2026 (in thousands):
Other information
Text added vs the prior filing · source: 10-Q · 2026-08-05
(2)On June 26, 2026, Dr. Urist entered into a Trading Plan, scheduled to commence on September 28, 2026 and end on October 9, 2026, providing for the sale of up to 100% of the Class A ordinary shares that may be issued upon settlement of EPAs in August 2026.
Text removed vs the prior filing · source: 10-Q · 2026-05-06
(2)Maximum shares subject to trading plan consists of up to 214,091 Class A ordinary shares and 100% of the shares that may be issued upon settlement of the EPAs awarded for the first and second quarters of 2026.
(3)On February 12, 2026, Dr. Urist entered into a Trading Plan, scheduled to commence on May 14, 2026 and end on May 26, 2026, providing for the sale of up to 27,368 Class A ordinary shares. In addition, on March 25, 2026, Dr. Urist entered into a Trading Plan, scheduled to commence on June 24, 2026…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice